The ACT trial, sponsored by Arizona State University, explores a non-pharmacological intervention combining aerobic exercise and cognitive training in older adults with amnestic mild cognitive impairment (aMCI). Given the high failure rate of drug trials for Alzheimer's disease, this study addresses a critical need for effective preventive strategies in high-risk populations. The trial's completion in July 2024 positions it to contribute valuable data to the growing market for cognitive health interventions, potentially influencing future therapeutic guidelines and creating opportunities for partnerships in behavioral health and wellness sectors. The results could also attract interest from investors focused on innovative approaches to neurodegenerative diseases.